From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

First Shipment of ANTHIM Anthrax Treatment Delivered to Strategic National Stockpile

by Global Biodefense Staff
October 10, 2017
Bacillus Anthracis - Anthrax

Elusys Therapeutics, Inc. announced today that the company has delivered the first doses of ANTHIM® (obiltoxaximab) Injection, its treatment for inhalational anthrax, to the U.S. Strategic National Stockpile (SNS), the U.S. Government’s repository of critical medical supplies for public health emergency preparedness.

The company is providing this delivery of ANTHIM as part of a procurement contract totaling $44.9M issued in 2015 by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (HHS ASPR).

ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage that leads to death. ANTHIM is supplied as single-dose vials for IV infusion.

ANTHIM received U.S. Food and Drug Administration (FDA) marketing approval in March 2016. ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Elusys has received over $240M in grants and contracts from the U.S. Department of Defense (DoD), National Institutes of Health (NIH), and BARDA, and is now partnering with the U.S. Centers for Disease Control and Prevention (CDC), which manages the SNS, to ensure that this lifesaving countermeasure can be provided in the event of an anthrax outbreak.

Elusys also announced today that it continues to make progress in developing an alternate dosage form for ANTHIM with the initiation of a manufacturing campaign to produce material for completion of the lyophilization (freeze drying) commercial process, in addition to providing product to complete the 2015 procurement order.

The lyophilized form of ANTHIM is expected to extend product shelf-life by several years. Lyophilization also may improve tolerance of ANTHIM to extreme temperatures during shipping and field use.

From Our Partners
Tags: AnthraxASPRBioterrorismHHSSelect AgentsStrategic National Stockpile

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC